Roy Soumitra, Clawson David S, Lavrukhin Oleg, Sandhu Arbans, Miller Jim, Wilson James M
Department of Pathology and Laboratory Medicine, Division of Transfusion Medicine, Gene Therapy Program, Translational Research Laboratory, 125 South 31st Street, Suite 2000, Philadelphia, PA 19104-3403, USA.
J Virol Methods. 2007 Apr;141(1):14-21. doi: 10.1016/j.jviromet.2006.11.022. Epub 2007 Jan 2.
The successful use of any adenoviral vectors is predicated upon the use of a serotype that is not neutralized by circulating antibodies. However, efforts to develop a diverse repertoire of serologically distinct adenovirus vectors may be hindered by the necessity to generate cell lines to allow for the successful propagation of vectors deleted of essential genes. A strategy to construct chimeric adenoviruses whereby the rescue and propagation of an E1-deleted HAdV-B-derived adenoviral vector can be achieved using existing cell lines such as HEK 293 is reported. It is further shown that this strategy may be more widely applicable.
任何腺病毒载体的成功应用都取决于所使用的血清型不会被循环抗体中和。然而，开发一系列血清学上不同的腺病毒载体的努力可能会受到阻碍，因为需要生成细胞系以成功繁殖缺失必需基因的载体。本文报道了一种构建嵌合腺病毒的策略，通过该策略可以使用诸如HEK 293等现有细胞系实现E1缺失的HAdV-B衍生腺病毒载体的拯救和繁殖。进一步表明，该策略可能具有更广泛的适用性。
